Cardinal Health (CAH) M&A Announcement summary
Event summary combining transcript, slides, and related documents.
M&A Announcement summary
8 Jul, 2026Deal rationale and strategic fit
Acquisitions of GI Alliance (GI MSO leader) and Advanced Diabetes Supply Group (direct-to-patient diabetes supplies) accelerate growth in specialty and at-home healthcare, expanding reach in key therapeutic areas and enhancing value for providers and patients.
GI Alliance provides a multi-specialty platform, expanding reach in the $40B GI market and building a network of over 900 physicians across 20 states and 345 locations.
ADSG strengthens at-home solutions, serving about 500,000 diabetes patients annually and enhancing direct-to-patient diabetes care.
Both deals align with a focused growth strategy in high-growth healthcare markets and support long-term value creation.
Financial terms and conditions
Acquiring 71% of GI Alliance for approximately $2.8B in cash, with a call right to purchase remaining equity on future anniversaries.
Acquiring ADSG for approximately $1.1B in cash; ADSG will merge with at-home solutions.
Transactions financed with ~25% cash on hand and ~75% new debt, including a $2.9B bridge loan facility.
Synergies and expected cost savings
Both acquisitions expected to deliver accretive revenue, segment profit, and non-GAAP EPS within 12 months post-close.
ADSG’s $1B revenue fits into the existing distribution network with no added capacity needed, enabling high-margin synergies.
Integration expected to enhance operational alignment, leverage existing business structures, and drive commercial and operational efficiencies.
Latest events from Cardinal Health
- Profit growth, raised guidance, and strategic M&A drive momentum and long-term resilience.CAH
Bank of America Global Healthcare Conference 20268 Jul 2026 - Specialty and diversified segments drive robust growth, with $10B+ cash flow expected.CAH
Baird Global Healthcare Conference 20258 Jul 2026 - Record FY24 results and raised FY25 guidance signal strong profit growth ahead.CAH
Q4 20248 Jul 2026 - Double-digit growth, innovation, and disciplined investment drive a strong outlook for the year.CAH
Evercore ISI 8th Annual HealthCONx Conference8 Jul 2026 - Non-GAAP EPS up 35% on 11% revenue growth; FY26 guidance raised amid tariff and litigation risks.CAH
Q3 20261 May 2026 - FY26 EPS guidance raised to at least $10, with specialty revenue to surpass $50B.CAH
44th Annual J.P. Morgan Healthcare Conference17 Apr 2026 - Double-digit profit growth and specialty expansion drive strong performance and future confidence.CAH
Leerink Global Healthcare Conference 20269 Mar 2026 - Q2 FY26 revenue up 19% to $65.6B, with strong profit growth and raised EPS guidance.CAH
Q2 20265 Feb 2026 - EPS guidance raised, specialty and growth businesses prioritized, and $10B+ cash flow targeted.CAH
Investor Day 20253 Feb 2026